Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/2047487320931622 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.
Biochem Pharmacol
January 2025
Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8655, Japan. Electronic address:
Lomitapide, a microsomal triglyceride transfer protein inhibitor, is a lipid-lowering drug that inhibits chylomicron formation in enterocytes and very low-density lipoprotein (VLDL) formation in the liver. Previous studies have shown that very low-density lipoprotein and/or low-density lipoprotein (VLDL/LDL) can deliver certain drugs in addition to lipids. Thus, we hypothesized that serum concentrations of drugs that are more likely to be distributed to VLDL/LDL in the serum (referred to as "VLDL/LDL-philic drugs" in this paper) may be altered by co-administered lomitapide.
View Article and Find Full Text PDFCurrent Status and Prospects of Regional Collaborative Pathways for Management of Acute Coronary Syndrome in Japan - A Nationwide Survey.
Circ J
January 2025
Department of Frontier Cardiovascular Science, Graduate School of Medicine, The University of Tokyo.
Background: Comprehensive management of acute coronary syndrome (ACS) requires seamless treatment across institutions, including intensive care centers and local clinics. However, maintaining guideline-directed medical therapy remains challenging. One promising option to improve the situation may be the implementation of regional collaborative clinical pathways.
View Article and Find Full Text PDFThe correlation between serum MHR and NLR and the severity of coronary lesions in NSTE-ACS patients of different genders.
Front Cardiovasc Med
January 2025
Department of Cardiovascular Medicine, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Background: To study the relationship between the monocyte/high-density lipoprotein cholesterol ratio (MHR) and neutrophil-to-lymphocyte ratio (NLR) and coronary artery stenosis in Non-st-elevation acute coronary syndromes (NSTE-ACS) patients of different genders.
Methods: A total of 253 control and 800 NSTE-ACS patients were included, and clinic data (29 items) were also collected. NSTE-ACS patients were divided into low-risk (0-23) and high-risk (≥ 23) groups based on the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) score.
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia.
Mol Diagn Ther
January 2025
Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, 4288A-1151 Richmond Street North, London, ON, N6A 5B7, Canada.
Clinical endpoints caused by hyperlipoproteinemia include atherosclerotic cardiovascular disease and acute pancreatitis. Emerging lipid-lowering therapies targeting proprotein convertase subtilisin/kexin 9 (PCSK9), lipoprotein(a), apolipoprotein C-III, and angiopoietin-like protein 3 represent promising advances in the management of patients with hyperlipoproteinemia. These therapies offer novel approaches for lowering pathogenic lipid and lipoprotein species, particularly in patients with serious perturbations who are not adequately controlled with conventional treatments or who are unable to tolerate them.
View Article and Find Full Text PDFFGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis.
J Transl Med
January 2025
Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Background: Acute pancreatitis (AP) presents a significant clinical challenge with limited therapeutic options. The complex etiology and pathophysiology of AP emphasize the need for innovative treatments. This study explores mRNA-based therapies delivering fibroblast growth factor 21 (FGF21) and apolipoprotein A1 (APOA1), alone and in combination, for treating experimental AP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!